Company / CIK 0001680581
Fulcrum Therapeutics, Inc.
- Ticker
- FULC
- Size, estimated from filings
- Micro cap (under $300M)
- Insiders on file
- 10
- Federal contracts on record
- none matched
- Lobbying filings on record
- 4
- SEC filings
- EDGAR ↗
- Latest trade on record
- July 17, 2026
Fulcrum Therapeutics, Inc. (FULC) has 10 insiders on file who disclosed 14 transactions in the last 12 months (6 open-market buys, 0 sales, about $1.5M at reported prices). No federal contract award that started in the last 180 days was found for a recipient with exactly this name, and 2 lobbying filings naming it as client report $110K in 2026.
Fulcrum Therapeutics, Inc. in charts
Who is trading this stock
Which people account for the buying and selling over the last 12 months?
1 person accounts for the disclosed buying and selling in Fulcrum Therapeutics, Inc. over the last 12 months; the most active is TANG KEVIN with $1.5M.
Lobbying spend by quarter
How much has Fulcrum Therapeutics, Inc. reported spending on federal lobbying?
Fulcrum Therapeutics, Inc. reported $190K in lobbying over the last eight quarters, from filings matched by exact company name.
Insiders
| Name | Role | Rows | Bought | Sold | Last filed |
|---|---|---|---|---|---|
| Sanofi | Insider | 3 | 1 | 0 | August 12, 2026 |
| TANG KEVIN | Insider | 6 | 6 | 0 | July 20, 2026 |
| Banks Sonja | Director | 1 | 0 | 0 | July 2, 2026 |
| Dorton Katina | Director | 1 | 0 | 0 | July 2, 2026 |
| Gould Robert J | Director | 1 | 0 | 0 | July 2, 2026 |
| Haviland Kate | Director | 1 | 0 | 0 | July 2, 2026 |
| King Rachel K. | Director | 1 | 0 | 0 | July 2, 2026 |
| GERAGHTY JAMES A | Director | 1 | 0 | 0 | July 2, 2026 |
| Hill Colin | Director | 1 | 0 | 0 | July 2, 2026 |
| Ezekowitz Alan | Director | 1 | 0 | 0 | July 2, 2026 |
Rows are this company's Form 4 rows for each person. "Bought" and "sold" count open-market purchases (code P) and sales only. More in insider buying and insider selling.
Insider transactions
| Filer | Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| TANG KEVIN | FULC | Buy P | July 17, 2026 | July 20, 2026 | 3d | 50,945 | $4 | $179K | indirect | Form 4 ↗ | |
| TANG KEVIN | FULC | Buy P | July 16, 2026 | July 20, 2026 | 4d | 116,671 | $4 | $415K | indirect | Form 4 ↗ | |
| TANG KEVIN | FULC | Buy P | July 15, 2026 | July 15, 2026 | 0d | 107,377 | $4 | $382K | indirect | Form 4 ↗ | |
| TANG KEVIN | FULC | Buy P | July 14, 2026 | July 15, 2026 | 1d | 75,952 | $4 | $272K | indirect | Form 4 ↗ | |
| TANG KEVIN | FULC | Buy P | July 14, 2026 | July 15, 2026 | 1d | 53,651 | $4 | $191K | indirect | Form 4 ↗ | |
| TANG KEVIN | FULC | Buy P | July 13, 2026 | July 15, 2026 | 2d | 12,966 | $4 | $46K | indirect | Form 4 ↗ | |
| Ezekowitz Alan | FULC | Other A | June 30, 2026 | July 2, 2026 | 2d | 32,000 | — | — | derivative | Form 4 ↗ | |
| Hill Colin | FULC | Other A | June 30, 2026 | July 2, 2026 | 2d | 32,000 | — | — | derivative | Form 4 ↗ | |
| GERAGHTY JAMES A | FULC | Other A | June 30, 2026 | July 2, 2026 | 2d | 32,000 | — | — | derivative | Form 4 ↗ | |
| King Rachel K. | FULC | Other A | June 30, 2026 | July 2, 2026 | 2d | 32,000 | — | — | derivative | Form 4 ↗ | |
| Haviland Kate | FULC | Other A | June 30, 2026 | July 2, 2026 | 2d | 32,000 | — | — | derivative | Form 4 ↗ | |
| Gould Robert J | FULC | Other A | June 30, 2026 | July 2, 2026 | 2d | 32,000 | — | — | derivative | Form 4 ↗ | |
| Dorton Katina | FULC | Other A | June 30, 2026 | July 2, 2026 | 2d | 32,000 | — | — | derivative | Form 4 ↗ | |
| Banks Sonja | FULC | Other A | June 30, 2026 | July 2, 2026 | 2d | 32,000 | — | — | derivative | Form 4 ↗ | |
| Sanofi | FULC | Exchange C | July 22, 2019 | July 23, 2019 | 1d | 3,250,000 | — | — | indirectderivative | Form 4 ↗ | |
| Sanofi | FULC | Buy P | July 22, 2019 | July 23, 2019 | 1d | 93,750 | $16 | $1.5M | indirect | Form 4 ↗ | |
| Sanofi | FULC | Exchange C | July 22, 2019 | July 23, 2019 | 1d | 464,285 | — | — | indirect | Form 4 ↗ |
Federal contracts (USAspending, awards started in the last 180 days)
No contract award starting in the last 180 days was found for a recipient named exactly "Fulcrum Therapeutics, Inc.". Subsidiaries and differently-spelled recipients are not matched — search contracts.
Lobbying (Senate LDA, as client)
| Period | Registrant | Primary issue | Amount | Source |
|---|---|---|---|---|
| 2026 Q2 | THE MCMANUS GROUP | Health Issues | $60,000 | LDA ↗ |
| 2026 Q1 | THE MCMANUS GROUP | Health Issues | $50,000 | LDA ↗ |
| 2025 Q4 | THE MCMANUS GROUP | Health Issues | $40,000 | LDA ↗ |
| 2025 Q3 | THE MCMANUS GROUP | Health Issues | $40,000 | LDA ↗ |
Related companies
Companies whose stock was traded by the same people who traded FULC, by number of filers in common. It shows overlap in public filings and nothing else.
- REGENERON PHARMACEUTICALS, INC. REGN 1 filer in common
- Organon & Co. OGN 1 filer in common
- Attovia Therapeutics, Inc. ATTO 1 filer in common
- Latigo Biotherapeutics, Inc. LTGO 1 filer in common
- Icosavax, Inc. ICVX 1 filer in common
- Inozyme Pharma, Inc. INZY 1 filer in common
- Translate Bio, Inc. TBIO 1 filer in common
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Lobbying disclosure reports Reports are due about 20 days after each quarter ends.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 11 | 17 | July 23, 2019 | July 20, 2026 | Form 4 list on EDGAR |
| Lobbying disclosure filings | 4 filings | — | — | — | LDA.gov search |
Site built October 22, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Insiders and their transactions come from SEC EDGAR Form 4 filings for this issuer. Contracts and lobbying are matched by exact normalized name (suffixes like Inc./Corp. ignored) to USAspending recipients and LDA clients — a conservative match that misses subsidiaries on purpose. See methodology and corrections.
Not investment advice. Public records shown as filed; no recommendation is made or implied.